# About Tirzepatide Legal | Research Digest > About this site: an independent editorial project publishing summaries of peer-reviewed research on tirzepatide. Not a clinic, not a vendor, not a prescriber. ## About this site Tirzepatide Legal is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the FDA-approved dual GIP/GLP-1 receptor agonist. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — trial records, FDA labeling, pharmacovigilance databases, and peer-reviewed journal publications. The domain modifier "legal" is an editorial framing: this site focuses on the regulatory and legal-status record — the approval timeline, the labeled indications, the boxed warnings, and the safety signals documented in the trial and post-market literature. It does not provide legal counsel, regulatory advice, or medical guidance. Why a dedicated reference site on tirzepatide? The peer-reviewed evidence base for this drug is large and growing. The SURPASS and SURMOUNT clinical programmes together span more than a dozen randomized controlled trials with tens of thousands of participants, and beyond-glycemia evidence continues to emerge from dedicated trials in heart failure, sleep apnea, and liver disease. That record deserves a plain, accurate, cited summary accessible to general readers — not promotional, not adversarial, just the documented science. Every quantitative claim on this site is cited to a specific published source. Every citation carries a DOI or PubMed URL. The reference list is on the [Tirzepatide references](/references) page. This site does not make dosing recommendations. It describes what was studied in which population, at which doses, with which outcomes — and it identifies the approved indications and labeled warnings from the FDA prescribing information. Nothing here constitutes medical advice. --- Regulatory record and trial data — stated plainly. Not a prescription, not a verdict.